Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Characteristics, treatment patterns, and survival among ALK + non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Second-generation ALK inhibitors are recently available for ALK+ non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. This study described characteristics, treatment sequencing, and outcomes among locally advanced/metastatic crizotinib-experienced ALK+ NSCLC patients.

          Related collections

          Author and article information

          Journal
          Lung Cancer
          Lung Cancer
          Elsevier BV
          01695002
          August 2016
          August 2016
          : 98
          : 9-14
          Article
          10.1016/j.lungcan.2016.05.004
          27393500
          © 2016

          https://www.elsevier.com/tdm/userlicense/1.0/

          Comments

          Comment on this article